B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.

Animals Antibodies, Monoclonal/immunology,therapeutic use Antibodies, Monoclonal, Humanized Antibody-Dependent Cell Cytotoxicity/immunology B-Lymphocytes/immunology,pathology Clinical Trials as Topic Disease Models, Animal Humans Lupus Erythematosus, Systemic/immunology,pathology,therapy Lymphocyte Depletion Lymphoma, Non-Hodgkin/immunology,pathology,therapy Rodentia Sialic Acid Binding Ig-like Lectin 2/immunology

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized CD22 protein, human Sialic Acid Binding Ig-like Lectin 2 epratuzumab